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Abstract
Background Obesity is a common risk factor for polycystic ovary syndrome (PCOS) and obstructive sleep apnoea (OSA). Both
PCOS and OSA are associated with increased risk of type 2 diabetes and cardiovascular disease. Hence, it is important to
determine the burden of OSA in women with PCOS.
Methods We searched electronic databases (MEDLINE, Embase, CINAHL, PsycINFO, Scopus, Web of Science, OpenGrey,
CENTRAL), conference abstracts, and reference lists of relevant articles, up to January 2019. No restriction for language or
publication status. Studies that examined the presence of OSA in women with PCOS using polysomnography and/or level III
devices were eligible for inclusion.
Results Seventeen studies involving 648 participants were included. Our meta-analysis showed that 35.0% (95% CI 22.2–
48.9%) of women with PCOS had OSA. This prevalence was not affected by variation in PCOS definition between studies.
Approximately one-tenth of the variation in OSA prevalence was related to differences in study population (higher in adults than
adolescents and mixed populations), and around one-tenth was related to sample size (higher in smaller studies). OSA prevalence
was markedly higher in obese versus lean women with PCOS, and in womenwith PCOS compared to controls (odds ratio = 3.83,
95%CI 1.43–10.24, eight studies, 957 participants (349 PCOS and 608 controls)). However, most of the studies were at high risk
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of selection bias, did not account for important confounders, included predominantly women with class II obesity, and were
conducted in one country (USA).
Conclusions Future studies need to examine the true prevalence of OSA in a more representative sample of women with PCOS.
Nevertheless, our results suggest that the prevalence of OSA in women with PCOS and obesity is high and clinicians should have
a high index of suspicion of OSA in these women.
Keywords PCOS . OSA . Hyperandrogenism . Obesity . Insulin resistance
Introduction
Polycystic ovary syndrome (PCOS) is the most frequent en-
docrine disorder in women of reproductive age, affecting
around one in ten women [1–6]. The Rotterdam criteria [7]
are widely used to diagnose PCOS, requiring the presence of
two of the following features: (i) hyperandrogenism (clinical
or biochemical), (ii) oligomenorrhoea/anovulation, and (iii)
polycystic ovaries on ultrasound, and the exclusion of condi-
tions with similar presentation [8]. PCOS carries a significant
burden on the overall health of affected women as it is asso-
ciated with multiple comorbidities, including obesity [9],
subfertility [10], cardiovascular disease (CVD) risk [11], type
2 diabetes mellitus (T2DM) [12], depression, and impaired
quality of life (QoL) [13–15]. Hyperandrogenism and obesity
that are commonly seen in women with PCOS are believed to
predispose these women to obstructive sleep apnoea (OSA)
[16, 17].
OSA is a common disorder with data from a recent system-
atic review showing that the prevalence of OSA in women in
the general population ranges from 6 to 19% [18]. OSA is
characterised by recurrent episodes of partial or complete up-
per airway obstruction during sleep [19]. These episodes are
associated with oxygen desaturations, sleep fragmentation,
change in intra-thoracic pressure, sympathetic overactivity,
and increase in heart rate and blood pressure [19, 20]. The risk
of OSA increases with older age, obesity, male gender,
smoking, alcohol intake, sedative use, menopause, and in cer-
tain ethnicities [19]. Similar to PCOS, OSA is a health burden
in affected individuals and it is associated with increased risk
of hypertension [21], CVD [22–24], mortality [25, 26], insulin
resistance (IR) and T2DM [27], road traffic accidents [28],
depression and impaired QoL [29–31], as well as subfertility
[32].
In a recent systematic review and meta-analysis, OSAwas
associated with worse metabolic profile in women with PCOS
[33]. However, despite its high prevalence and clinical impli-
cations, OSA often remains undiagnosed particularly in wom-
en [19, 34]. A few studies have suggested a high prevalence of
OSA in women with PCOS [16, 35]. This is also supported by
the Endocrine Society clinical practice guideline [36] which
states in its evidence analysis that ‘women with PCOS devel-
op OSA at rates that equal or exceed those in men’. However,
the reported prevalence of OSA in women with PCOS has
been very wide, ranging from 0 to 70% [17, 37], which raises
concerns about the methodologies used in these studies.
Similarly, a recent meta-analysis has attempted to answer this
question [38]; however, the review contained significant
methodological weaknesses that question its validity (‘OSA
prevalence in PCOS’ in discussion). To date, there is no com-
prehensive, well-conducted, systematic review that examined
the prevalence of OSA in women with PCOS. Assessing the
prevalence of OSA in women with PCOS will allow the im-
plementation of appropriate screening strategies and further
development of clinical studies to examine the impact of
OSA in women with PCOS. This is particularly important as
OSA is a treatable condition, and it is associated with signif-
icant comorbidities [39].
Objectives
To assess the prevalence of OSA in women with PCOS based
on the existing literature.
Methods
The protocol for this review was prospectively registered with
PROSPERO: CRD42016041464 (http://www.crd.york.ac.uk/
PROSPERO/) and is reported following the meta-analysis of
Observational Studies in Epidemiology (MOOSE) guidelines
[40].
Selection criteria
Human studies, interventional or observational, that examined
the presence of OSA in women with PCOSwere included.We
included studies that used polysomnography or level III de-
vices to diagnose OSA, regardless of the cut-offs used.
Conference abstracts and published studies were included.
All women with PCOS were included regardless of age
(adults (premenopausal and postmenopausal) and adolescents
(postmenarchal)), ethnicity, or PCOS diagnostic criteria.
Exclusion criteria are the following: conditions with pre-
sentation similar to PCOS including congenital adrenal hyper-
plasia, Cushing’s syndrome, prolactinomas, thyroid disease,
and androgen-secreting tumours.
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Primary outcome
Prevalence of OSA in women with PCOS.
Secondary outcomes
Prevalence of OSA in subpopulations of women with PCOS
(obese, non-obese, adolescents, and adults).
Search strategy
The initial literature search was performed on 11 April 2016
and updated on 7 February 2017, and on 11 January 2019. The
searchwas not restricted by language or publication status.We
searched Embase (Ovid), MEDLINE (Ebsco), PsycINFO
(ProQuest), Scopus, CINAHL (Ebsco), OpenGrey, Web of
Science, Cochrane Central Register of Controlled Trials
(CENTRAL), and abstracts from major conferences. The ref-
erence lists of relevant papers and review articles were manu-
ally searched. The search strategy is provided in Appendix 1
(online data supplement).
Selection of studies
Two authors (HK and IK) independently screened titles and
abstracts. All potentially relevant articles were reviewed in
full. Any disagreements between the two authors were re-
solved by consensus and, if necessary, discussion with a third
author (OU).
Data extraction and management
Two authors (HK and IK) independently extracted data. In
case of multiple publications, we included the main study
report/paper and, where necessary, additional details extracted
from secondary papers. Study investigators were contacted to
resolve any data queries, as required. For duplicate publica-
tions, we contacted study investigators to clarify the original
publication, and if no response was received, we chose the
study with the largest number of participants. We extracted
the following details from each study: study design, partici-
pants’ characteristics, and prevalence estimates.
Risk of bias
Two authors (HK and IK) independently assessed the risk of
bias. Any disagreements between the two authors were re-
solved by consensus and discussion with a third author
(OU), if necessary. We used the Risk of Bias Assessment
Tool for Non-Randomised Studies (RoBANS) [41] to assess
the risk of bias for included study. We assessed the following
domains: selection bias (sample population), selection bias
(confounding variables), performance bias (measurement of
exposure), performance bias (analytical methods to control
for bias), and other bias. The methodological components of
the studies were assessed and classified as high risk, low risk,
or unclear.
Unit of analysis
Number of women with OSA in a population of women with
PCOS.
Data synthesis
We pooled the prevalence estimates using the DerSimonian–
Laird random effects model [42]. We assessed the between
study variations in prevalence estimates using the Higgins I2
statistic, and, as recommended, a value of greater than 50%
was considered for moderate heterogeneity [43, 44]. We con-
ducted series of meta-regression and subgroup analyses to
explore the effect of study-level covariates on the prevalence
estimates. The following study-level factors were considered:
type of publication (conference abstract or journal article),
year of publication (earlier studies: 2001 to 2009 or recent
studies: 2010 to 2015), country, population (adults, adoles-
cent, or mixed population), body mass index (non-obese ver-
sus obese), sample size, and PCOS definition (National
Institutes of Health (NIH) definition [45], Rotterdam criteria
[7], or not reported). The possibility of reporting bias was
assessed using an Egger’s test and funnel plot [46]. Leave-
one-study-out sensitivity analysis was also performed to as-
sess the stability of the meta-analysis result [47]. Stata 14 was
used for all analyses (StataCorp, College Station, TX).
Results
Search results and study characteristics
The search results are shown in a PRISMA flow diagram
(Fig. 1). Main characteristics of the 17 included and 15 ex-
cluded studies are summarised in Table 1 and Table S1 (in the
online data supplement), respectively. All of the included
studies used polysomnography to diagnose OSA and were
reported in English. Five studies did not specify the cut-offs
used to diagnose OSA; three studies used an apnoea/
hypopnoea index (AHI) > 5 events per hour, and nine studies
used variable diagnostic criteria (Table 1).
Risk of bias of included studies
The risk of bias assessment summary for each study is pre-
sented in Fig. 2. The selection bias due to inadequate selection
of participants was high in five studies and unclear in the
remaining 12 studies. The selection bias caused by the
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inadequate confirmation and consideration of confounding
variables was high in most of the studies (15 out of 17 studies)
and low only in one study. The performance bias due to inad-
equate measurement of exposure was low in 12 studies, high
in two studies, and unclear in the remaining three studies. The
detection bias due to inadequate blinding of outcome assess-
ments was low in most studies (16 out of 17 studies) and high
only in one study. The attrition bias due to inadequate han-
dling of incomplete outcome data was low in all 17 studies.
The reporting bias due to selective reporting was low in most
studies (16 out of 17 studies) and high in one study.
Overall prevalence of OSA in women with PCOS
The prevalence of OSA in women with PCOS and 95%
CIs from individual studies with a pooled estimate are
shown in Fig. 3. The pooled prevalence of OSA for all
studies yielded an estimate of 35.0% (95% CI 22.2 to
48.9%) of women with PCOS. The I2 statistic was 92%,
indicating statistically significant heterogeneity among
the studies. The contour-enhanced funnel plot of exam-
ination of publication bias is shown in Fig. S1 in the
online data supplement. We found no evidence of pub-
lication bias as indicated by the relatively symmetrical
funnel plot of studies’ precision against prevalence esti-
mates (in logarithmic scale). This was confirmed when
formally tested using the Egger method (p value for
small study bias = 0.063). The results of leave-one-
study-out sensitivity analyses showed that no study
had undue influence on the pooled OSA prevalence;
see Fig. S2 in the online data supplement.
Prevalence of OSA by different subgroups
The results of subgroup analyses are shown in Fig. 4.
There is no evidence of statistically significant differ-
ence in the pooled prevalence of OSA by type of pub-
lication, publication year, or sample size. Studies pub-
lished in the USA tended to report higher prevalence of
OSA than studies from other countries (43.7% versus
22.8%); however, this difference did not reach a statis-
tically significant level (p = 0.725). Compared to studies
that used the NIH PCOS definition, studies that used
the Rotterdam criteria and those not reporting how
PCOS was diagnosed tended to have higher OSA prev-
alence, albeit not statistically significant. Two studies
stratified the prevalence estimates by body mass index,
i.e. non-obese versus obese women (Fig. 5). For both
studies, the prevalence of OSA was 0% in the non-
obese population. In the Gateva and colleagues study
[51], two of the six obese women had OSA (33%),
while in the Kenigsberg and colleagues study [52], nine
out of 22 obese women had OSA (41%). When these
two studies were pooled, the prevalence of OSA was
38% higher in women with obesity and PCOS com-
pared to non-obese women with PCOS (prevalence dif-
ference = + 37.9%, 95% CI 15.0 to 60.9%).
Factors modifying the prevalence of OSA as identified
by meta-regression analysis
Factors associated with prevalence estimates and propor-
tion of explained variability in prevalence estimates as
identified by meta-regression analyses are shown in
Table S2 in the online data supplement. In a series of
meta-regression analyses, none of the study-level factors
were significantly associated with the prevalence esti-
mates. However, approximately one-tenth of the between
study variation in the prevalence estimates was explained
by the variations in the study sample size (higher in small-
er studies), and around one-tenth was related to differ-
ences in the study population (higher in adults compared
to adolescents and mixed populations).
Discussion
Our analysis of the existing data suggests that OSA prevalence
in women with PCOS is high. This is mainly driven by studies
that were conducted in the USA, included women with PCOS
and class II obesity, and had a relatively high level of selection
bias. Accordingly, it is difficult to draw firm conclusions about
the true prevalence of OSA in women with PCOS based on
the available data. As expected, the prevalence of OSA in
women with PCOS appears to increase with age and obesity.
Fig. 1 PRISMA flow diagram
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OSA prevalence in PCOS
Based on our meta-analysis, OSA is present in almost one-
third of women with PCOS. In the recent meta-analysis by
Helvaci et al., the prevalence of OSA was lower at 0.22
(95% CI 0.08–0.40) in women with PCOS [38]. The lower
OSA prevalence reported could be explained by differences in
study methodology. In the study by Helvaci et al., the litera-
ture search was limited to two electronic databases, was re-
stricted to studies published in English language, and did not
include ‘grey literature’ (for example, conference abstracts).
In addition, in their meta-analysis, Helvaci et al. included du-
plicate publications [50, 61–63], and one study with 0% prev-
alence of OSA as only women without OSA were recruited
[64].
The prevalence of OSA inwomen in the general population
has been reported at 6–19% [18]. Seven studies have com-
pared OSA prevalence in women with PCOS to matched con-
trols, and the majority [16, 35, 54, 56, 57] have shown OSA to
be more prevalent in women with PCOS (Table 2). Women
with PCOS were four times more likely to have developed
OSA than controls (odds ratio = 3.83, 95% CI 1.43–10.24,
eight studies, 957 participants) (Fig. 6). However, important
confounding factors that are known to affect the risk of OSA
Fig. 2 Risk of bias of included studies
Fig. 4 Pooled prevalence of obstructive sleep apnoea (OSA) by different
subgroup
Fig. 3 Pooled prevalence of obstructive sleep apnoea (OSA)
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have not been adequately considered in these studies, includ-
ing obesity [16], abdominal adiposity [16, 35, 54, 56], and
ethnicity [16, 54]. Moreover, while controls were recruited
from the general population [16, 35, 56], women with PCOS
were recruited from specialised clinics [35, 37, 56]. In addi-
tion, PCOS was not formally ruled out in controls [16].
Subsequently, it is not clear if women with PCOS in the com-
munity are at higher risk of OSA compared to age- and
adiposity-matched controls. Well-conducted large observa-
tional studies in the general population are needed to answer
this question.
Factors affecting OSA prevalence in PCOS
We found a trend for OSA to be more common in adult wom-
en with PCOS compared to adolescents, and in women with
PCOS and obesity compared to women with PCOS without
obesity. This is not surprising as the risk of OSA in the general
population increases with increasing age and obesity [19, 65].
Therefore, it is likely that PCOS precedes the development of
OSA, particularly as features of PCOS have been identified in
prepubertal girls [66, 67]. However, it is also possible that
OSA may precede the development of PCOS in some women
[68]; for example, a third of the adolescent girls with PCOS in
the study by Nandalike et al. [54] had a previous history of
tonsillectomy, and tonsillitis and/or tonsillar enlargement are
the most common cause of OSA in children [69].
The limited data available suggest that OSA prevalence is
low in women with PCOS who are lean/non-obese. This is
based on three studies that reported data on a total of 40 par-
ticipants with these characteristics [37, 51, 52]. However, the
sample size is too small to draw firm conclusions.
Androgens are believed to play a role in the pathogenesis of
OSA and may contribute to the higher prevalence of OSA in
men compared to women [19]. However, despite the higher
levels of testosterone and/or free testosterone in the PCOS
group compared to controls in three studies [37, 50, 53], there
was no difference in OSA prevalence (Table 2). Furthermore,
while some studies showed the severity of OSA in women
with PCOS to correlate with hyperandrogenism [35]; others
did not show a similar relationship [56]. In addition, while
women with PCOS diagnosed based on the NIH definition
are expected to show higher degree of hyperandrogenism
compared to those diagnosed using the Rotterdam criteria,
we did not find a significant difference in OSA prevalence
based on the PCOS diagnostic criteria/definition used.
Subsequently, based on the existing data, the role of
hyperandrogenism in influencing OSA risk in women with
PCOS is probably small, which might be due to the relatively
lower levels of androgens in women with PCOS compared to
men.
Large cohort studies with long duration of follow-up are
needed to clarify the natural history and relationship between
PCOS, OSA, and obesity.
PCOS and OSA... chicken-and-egg?
While obesity is a shared feature between PCOS and OSA that
may contribute to the high prevalence of OSA in women with
PCOS reported in some studies, other factors may also play an
important role in how these two conditions interact [68].
PCOS may contribute to the pathogenesis of OSA through
its association with hyperandrogenism and low progesterone
levels and may lead to increased upper airway collapsibility,
and/or changes in the sensitivity and responsiveness of the
ventilatory chemoreceptors [70].
On the other hand, OSAmay contribute to the pathogenesis
of PCOS through promoting the following: (i) IR [71]; (ii)
oxidative stress [72], which may exacerbate IR [73] and con-
tribute to infertility through disruption of the meiotic spindle
formation in the oocyte [74]; and (iii) increased sympathetic
activity that may lead to IR, altered ovarian function, and the
development polycystic ovarian morphology [75, 76].
Subsequently, it is plausible that the relationship between
PCOS and OSA is bidirectional [33, 68] (Fig. S3 in the online
data supplement). Understanding this relationship is impor-
tant, as many of the mechanisms through which OSA might
impact on PCOS (e.g. IR, inflammation [77], oxidative stress,
and sympathetic activation) are amenable to treatment with
continuous positive airway pressure (CPAP) [78, 79]. In addi-
tion, due to the increased risk of road traffic accidents in pa-
tients with OSA, it is important to identify these patients as
CPAP lowers this risk [80]. Well-conduced longitudinal large
cohort studies and randomised controlled trials are needed to
assess the exact relationship between these two common
conditions.
Study limitations
We found high heterogeneity in the reported studies.
However, this is not unexpected in observational studies. We
conducted meta-regression analyses to explore between
study-level factors that could explain the observed between
Fig. 5 Obstructive sleep apnoea (OSA) prevalence difference in women
with PCOS and obesity versus women with PCOS without obesity. In the
study by Gateva et al., the cut-offs used to define obesity in women with
PCOS were not reported. Kenigsberg et al. included females with PCOS
between the ages of 13–21 years and defined obesity as a BMI z-score >
95th percentile, while participants with BMI z-score < 85th percentile
were considered lean
Sleep Breath
Ta
bl
e
2
C
ha
ra
ct
er
is
tic
s
of
st
ud
ie
s
co
m
pa
ri
ng
ob
st
ru
ct
iv
e
sl
ee
p
ap
no
ea
(O
SA
)p
re
va
le
nc
e
in
w
om
en
w
ith
po
ly
cy
st
ic
ov
ar
y
sy
nd
ro
m
e
(P
C
O
S)
to
co
nt
ro
ls
[o
rd
er
ed
al
ph
ab
et
ic
al
ly
ba
se
d
on
th
e
fi
rs
ta
ut
ho
r’
s
su
rn
am
e]
St
ud
y
C
ou
nt
ry
Po
pu
la
tio
n
O
SA
PC
O
S
C
on
tr
ol
s
P
(O
SA
%
)
N
ot
es
D
ia
gn
os
is
m
et
ho
d
N
A
ge
(y
r)
B
M
I
(k
g/
m
2
)
O
S
A
(%
)
N
A
ge
(y
r)
B
M
I
(k
g/
m
2
)
O
S
A
(%
)
P
C
O
S
ve
rs
us
co
nt
ro
ls
de
So
us
a
20
12
[5
0]
G
er
m
an
y
A
do
le
sc
en
ts
P
SG
35
15
.2
±
1.
0
33
.2
±
6.
8
0.
0%
19
15
.2
±
1.
1
32
.4
±
3.
9
0.
0%
N
S
H
O
M
A
-I
R
an
d
an
dr
og
en
le
ve
ls
w
er
e
hi
gh
er
in
su
bg
ro
up
s
of
gi
rl
s
w
ith
P
O
C
S
th
an
co
nt
ro
ls
.
Fo
ge
l2
00
1
[3
5]
U
SA
A
du
lts
PS
G
18
31
.1
±
5.
5
36
.9
±
5.
5
72
%
18
32
.3
±
5.
5
36
.9
±
5.
9
39
%
0.
10
W
om
en
w
ith
PC
O
S
ha
d
hi
gh
er
w
ai
st
-t
o-
hi
p
ra
tio
an
d
te
st
os
te
ro
ne
le
ve
ls
.
N
an
da
lik
e
20
12
[5
4]
U
SA
A
do
le
sc
en
ts
P
SG
28
16
.8
±
1.
9
44
.8
±
8.
8
57
.1
%
28
17
.1
±
1.
8
40
.2
±
4.
7
14
.3
%
<
0.
01
O
nl
y
gi
rl
s
w
ith
sy
m
pt
om
s
w
er
e
te
st
ed
.N
o
di
ff
er
en
ce
in
B
M
I
z-
sc
or
es
be
tw
ee
n
gr
ou
ps
.M
or
e
gi
rl
s
in
th
e
PC
O
S
gr
ou
p
(3
2%
)
ha
d
a
hi
st
or
y
of
ad
en
ot
on
si
lle
ct
om
y
(t
re
at
m
en
to
f
ch
oi
ce
fo
r
O
S
A
in
ch
ild
re
n)
pr
io
r
to
P
S
G
co
m
pa
re
d
co
nt
ro
ls
(1
0.
7%
).
Ta
sa
li
20
08
[5
6]
U
SA
A
du
lts
PS
G
52
29
.7
±
5.
1
39
.2
±
7.
2
55
.8
%
21
30
.7
±
5.
0
36
.0
±
6.
9
19
%
0.
01
T
he
au
th
or
s
ad
ju
st
ed
fo
rB
M
Ia
nd
et
hn
ic
ity
in
th
ei
r
an
al
ys
is
of
O
S
A
pr
ev
al
en
ce
.
Te
m
pl
e
20
13
[5
7]
U
SA
A
du
lts
PS
G
12
9
28
.2
±
5.
7
38
.6
±
6.
8
48
.1
%
46
31
.0
±
6.
1
39
.4
±
7.
5
41
%
0.
03
T
he
au
th
or
s
ad
ju
st
ed
fo
r
ag
e,
B
M
I,
an
d
ra
ce
in
th
ei
ra
na
ly
si
s
of
O
S
A
pr
ev
al
en
ce
.
V
go
nt
za
s
20
01
[1
6]
U
SA
M
ix
ed
(1
6–
45
yr
)
P
SG
53
30
.4
±
6.
6
38
.7
±
8.
0
11
.3
%
45
2
32
.1
±
6.
4
26
.4
±
6.
4
0.
4%
<
0.
00
01
D
es
pi
te
th
e
au
th
or
s
ad
ju
st
in
g
fo
r
B
M
I,
st
at
is
tic
al
ad
ju
st
m
en
ti
s
un
lik
el
y
to
fu
lly
ex
cl
ud
e
an
ob
es
ity
-r
el
at
ed
ef
fe
ct
on
O
SA
pr
ev
al
en
ce
as
th
e
di
ff
er
en
ce
in
B
M
I
w
as
hi
gh
(1
2.
3
kg
/m
2
).
W
oo
tto
n
20
17
[5
9]
U
S
A
A
do
le
sc
en
ts
P
SG
16
N
R
N
R
50
%
14
N
R
N
R
57
.1
%
N
S
To
ta
lN
=
30
gi
rl
s,
ag
e
14
–1
8
ye
ar
s;
an
d
m
ea
n
B
M
I
37
.2
kg
/m
2
(r
an
ge
22
–5
5
kg
/m
2
).
N
o
in
fo
rm
at
io
n
on
ho
w
pa
rt
ic
ip
an
ts
w
er
e
se
le
ct
ed
,o
rd
if
fe
re
nc
es
be
tw
ee
n
su
bg
ro
up
s
in
ag
e,
B
M
I,
et
c.
Y
an
g
20
09
[3
7]
Ta
iw
an
A
du
lts
PS
G
18
29
.1
±
6.
1
21
.7
±
2.
4
0.
0%
10
31
.6
±
12
.3
20
.9
±
1.
8
0.
0%
N
S
P
C
O
S
gr
ou
p
ha
d
hi
gh
er
te
st
os
te
ro
ne
le
ve
ls
an
d
la
rg
er
w
ai
st
ci
rc
um
fe
re
nc
e
an
d
W
H
R
co
m
pa
re
d
to
co
nt
ro
ls
.
D
at
a
pr
es
en
te
d
as
m
ea
n
±
st
an
da
rd
de
vi
at
io
n
B
M
Ib
od
y
m
as
s
in
de
x,
H
O
M
A
-I
R
ho
m
eo
st
at
ic
m
od
el
as
se
ss
m
en
to
f
in
su
lin
re
si
st
an
ce
,W
H
R
w
ai
st
-t
o-
hi
p
ra
tio
,N
sa
m
pl
e
si
ze
,N
R
no
tr
ep
or
te
d,
N
S
no
ts
ig
ni
fi
ca
nt
,O
SA
ob
st
ru
ct
iv
e
sl
ee
p
ap
no
ea
,O
SA
%
O
SA
pr
ev
al
en
ce
,P
C
O
S
po
ly
cy
st
ic
ov
ar
y
sy
nd
ro
m
e,
P
SG
po
ly
so
m
no
gr
ap
hy
,y
r
ye
ar
s
Sleep Breath
study heterogeneity and found that the study population (i.e.
adolescents, adults, mixed), and study sample size each ex-
plained around one-tenth of the noted heterogeneity. In addi-
tion, to prevent wrong or misleading conclusions, meta-
analysis rather than narrative synthesis has been recommend-
ed even in the presence of high between study variations in the
prevalence estimates. Examining the effects of the different
cut-offs used to diagnose OSA on its prevalence was not pos-
sible as, while some studies reported AHI, others reported
RDI or AI when diagnosing OSA, and five studies did not
report how OSAwas diagnosed. The majority of studies that
examined OSA prevalence in PCOS was found to be at high
risk of selection bias and did not account for important con-
founding factors. Subsequently, the prevalence of OSA in
women with PCOS reported in this systematic review should
be viewed with some caution.
We would like to note a few deviations from our
original protocol: we included studies that used level
III devices, in addition to polysomnography, as they
are validated and approved methods to diagnose OSA
[81]. However, all the studies we identified have used
polysomnography to diagnose OSA. We accepted the
study authors’ own definitions of OSA and PCOS, re-
gardless of the diagnostic criteria used. In five confer-
ence abstracts and two journal articles, the authors did
not report the criteria used to diagnose OSA and/or
PCOS (Table 1). However, we do not believe that these
deviations affected our results since we did not find a
significant difference in OSA prevalence between con-
ference abstracts and journal articles, neither did we
find a difference in OSA prevalence based on the
PCOS diagnostic criteria used. In addition, the AHI
threshold to diagnose OSA differs between children
and adults.
Study strengths
We conducted and reported this systematic review and meta-
analysis following internationally recognised recommenda-
tions. We have searched a large number of databases/sources
to identify relevant articles, and our search was not restricted
by study design, language, or publication type or year.
Conclusions
Obstructive sleep apnoea appears to affect a third of women
with polycystic ovary syndrome, but this is mainly driven by
studies that recruited women with class II obesity and had
significant limitations. Whether, and to what extent, women
with PCOS are at increased risk of OSA, compared to women
without PCOS, remains unclear.Well-conducted, large, cohort
studies in the general population with extended follow-up are
required to assess the true prevalence of OSA in women with
PCOS and to examine the natural history and relationship
between PCOS, OSA, and obesity.
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